Fast Company November 18, 2021
Sherlock Biosciences’ first-ever use of CRISPR in a diagnostic has huge potential for at-home COVID-19 testing and beyond.
This article is about one of the honorees of Fast Company’s first Next Big Things in Tech awards. Read about all the winners here.
In January 2020, CRISPR startup Sherlock Biosciences was in the middle of working on CRISPR-based tests that could deliver lab quality testing at home for common illnesses like flu or sexually transmitted infections like chlamydia or gonorrhea. When COVID-19 struck, the company quickly got to work on a lab test for it.
Within two months, the company submitted its CRISPR-based test to the Food and Drug Administration for emergency use authorization. In May, the FDA gave its authorization,...